XML 39 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration and Licensing Agreements (Tables)
12 Months Ended
Dec. 31, 2021
Collaboration and Licensing Agreements  
Schedule of revenue by licensees

The $275.1 million, $122.7 million, and $156.7 million of revenue recorded for the years ended December 31, 2021, 2020, and 2019, respectively, were earned principally from the following licensees (in millions):

Year Ended

 

December 31, 

 

2021

2020

2019

 

Aimmune

    

$

    

$

9.6

    

$

Alexion

22.2

 

26.2

 

13.0

Amgen

 

 

5.0

Astellas

 

3.5

 

14.0

Genentech

2.5

 

3.5

 

113.9

Gilead

 

13.5

 

Janssen

113.8

MorphoSys

18.4

 

39.0

 

Novartis

43.1

 

 

10.0

Omeros

 

5.0

 

Vir

52.7

 

0.3

 

0.8

Viridian

7.5

 

6.0

 

Zenas

14.9

 

16.1

 

Total

$

275.1

$

122.7

$

156.7

Schedule of disaggregation of revenue

Year Ended

December 31, 

2021

2020

2019

Research collaboration

    

$

93.0

    

$

4.5

    

$

16.3

Milestone

21.0

 

50.2

 

23.2

Licensing

80.8

 

50.2

 

112.2

Royalties

80.3

 

17.8

 

5.0

Total

$

275.1

$

122.7

$

156.7